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http://www.biomedcentral.com/1471-2377/13/78RESEARCH ARTICLE Open AccessDevelopment of a short form and scoring
algorithm from the validated actionable bladder
symptom screening tool
David Bates1, Jack Burks2*, Denise Globe3, Manuel Signori3, Stacie Hudgens4, Pierre Denys5, Scott MacDiarmid6,
Victor Nitti7, Ib Odderson8, Amy Perrin Ross9 and Michael Chancellor10Abstract
Background: The majority of multiple sclerosis (MS) patients develop some form of lower urinary tract dysfunction,
usually as a result of neurogenic detrusor overactivity (NDO). Patients identify urinary incontinence as one of the
worst aspects of this disease. Despite the high prevalence of NDO, urological evaluation and treatment are
significantly under-accessed in this population. The objectives of this study were: 1) to adapt the previously
validated Actionable Bladder Symptom Screening Tool (ABSST) to a short form for ease and brevity of application in
a clinical setting that is clinically meaningful; and 2) to develop a scoring algorithm that would be interpretable in
terms of referring/considering precise diagnosis and treatment.
Methods: A US-based, non-randomized, multi-center, stand-alone observational study was conducted to assess the
psychometric properties of the ABSST among patients who have MS with and without NDO. Mixed psychometric
methods (e.g., classical statistics (Psychometric theory (3rd ed.). New York: McGraw-Hill; 1994) and item response
methods (Applying the Rasch Model: Fundamental Measurement in the Human Sciences. New Jersey: Lawrence
Earlbaum Associates; 2001)) were used to evaluate the predictive and clinical validity of the shortened form. The
latter included clinicians flagging clinically meaningful items and associated response options which would indicate
the need for further evaluation or treatment.
Results: A total of 151 patients, all with MS and with and without NDO, were recruited by 28 clinicians in various
US geographical locations. Approximately 41% of patients reported a history of or currently having urinary
incontinence and/or urinary urgency. The prediction model across the entire range of classification thresholds was
evaluated, plotting the true positive identification rate against the false positive rate (1-Specificity) for various cut
scores. In this study, the cut-point or total score of greater than or equal to 6 had a sensitivity of approximately
85%, and specificity of approximately 93% (i.e., 85% patients would warrant being referred to a urologist and 93%
of the patients whose symptoms would not warrant urologist referral).
Conclusions: Overall the short form ABSST demonstrated sensitivity and specificity as it maintained the integrity of
the longer form tool. Concurrent validity for each subscale as well as predictive and concurrent validity of the total
shortened instrument was demonstrated. This instrument provides a new method for assessing bladder problems
among MS patients, and may facilitate earlier and more precise diagnosis, treatment, and/or referral to a specialist.
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Multiple sclerosis (MS) is a progressive neurologic dis-
order that causes demyelination of affected nerves in the
central nervous system [1-3]. MS can cause almost any
neurological symptom, and it often progresses to cogni-
tive and neurological disabilities in the patient, including
a decline in mobility [1]. MS affects women three times
as often as it affects men. It affects approximately 1 in
1000 people in the US and is the most common cause of
neurological disability in individuals 20–45 years old
[4,5]. A majority of MS patients develop some form of
lower urinary tract dysfunction due to disconnection be-
tween the brainstem and the lower spinal cord [6-8]. In
particular, up to 75% of MS patients have neurogenic de-
trusor overactivity (NDO), a bladder disorder character-
ized by spontaneous overactivity of the detrusor muscle
[9]. Symptoms of this disorder include urinary urgency,
urinary frequency, and/or urinary incontinence [2,10].
Incontinence has been identified as one of the worst as-
pects of the disease from the patient’s perspective [8].
High intravesical pressures may also lead to serious
complications, including kidney infection, and reflux, ul-
timately causing irreversible damage [7]. Additionally,
given all of the issues with NDO in MS it is noted that
research groups are establishing guidelines for the evalu-
ation of urinary disorders in MS [7,8,11]. Therefore,
despite the high prevalence of urinary incontinence, uro-
logical evaluation and treatment are significantly under-
accessed in this population [10]. This study outlines the
development and validation of a shortened form of a
new screening tool, the Actionable Bladder Symptom
Screening Tool (ABSST), that healthcare providers can
use to identify MS patients with urinary incontinence
who may be in need of a more precise diagnosis and/or
treatment for their urologic symptoms, including referral
to a urologist. The objectives of this study were twofold:
1) to adapt the previously validated 17-item ABSST to a
short form for ease and brevity of application in a med-
ical setting that is clinically meaningful; and 2) to de-
velop a scoring algorithm that would be interpretable in
terms of referring/considering diagnosis and treatment.
Novel item response and classical test methods were
used to identify optimally performing items for inclusion
in the short form assessment.
In view of recent research suggesting that patients and
clinicians are more likely to use shorter instruments
[12-15], it was decided to develop a short form version
of the ABSST that is clinically meaningful from the clini-
cian’s perspective. The development of this short form
version of the instrument is described here. In addition,
a scoring algorithm was developed for the ABSST, with
a identification of a score that would recommend further
diagnosis or referral to a urologist. The novel approach
of developing the scoring algorithm presented here isbased on pivot anchoring as a means of demonstrating
clinical meaningfulness.
Methods
Multi-site observational study
Data to support the short form adaptation was collected
in a US-based, non-randomized, multi-center, stand-
alone observational study in male and female patients
who have MS with and without NDO. MS patients were
recruited through neurology practices to complete pa-
tient reported outcome assessments (PRO) (the ABSST
and the Overactive Bladder Questionnaire – Short Form
(OAB-q-SF)) as well as a demographic and health infor-
mation form. Written informed consent was needed be-
fore the subject could participate in any part of the
study. All research involving patient interviews and pa-
tient completion of questions were in compliance of the
Helsinki Declaration and had full Institutional Review
Board (IRB) approval from Copernicus Group (an inde-
pendent institutional review board organized and operat-
ing in compliance with regulations governing institutional
review boards set forth in 21 CFR and ICH guidelines, as
well as 45 CFR when applicable.) (Protocol # MAP1-
11-049). Completed ABSST questionnaires (with patient
specific identifying information removed) were shared
with the referring clinician and the clinician denoted
whether or not referral to a urologist was recommended
based on the specific patient’s responses. The presence of
NDO was not a requirement for inclusion into the obser-
vational study. Details of the design of the multi-site ob-
servational study will be reported in a separate publication
summarizing the development and validation of the
ABSST long form [16].
Psychometric criteria/methods for inclusion on the
ABSST-short form
The psychometric evaluation and subsequent develop-
ment of the ABSST-Short Form integrated responses on
the longer version of the tool collected from both pa-
tients and clinicians. A set of predefined statistical cri-
teria was developed and tested to ensure that the
resulting shortened tool included clinically meaningful
and reliable items. These were as follows:
 Classical statistical methods
Percentage of patient responses at the floor of
measurement (lowest response option) less than
50% [17].
Item correlation with the overall scale (e.g., the
extent to which the items are related to other
items on the scale) greater than 80% [17].
 Item response theory methods
Degree to which patients response as expected
(e.g. measurement error) as measured by Rasch
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0.60 and 1.40).
 Clinician perspective
Greater than 50% of clinicians indicated that the
item was clinically relevant.
For clinician response, a pivot anchoring approach was
used. In this analysis, the 23 recruiting clinicians were
asked to review the ABSST, circle the items that were
important to them, and indicate the threshold at which
they thought the items would indicate a potential blad-
der problem or be a cause for concern [18,19].
Classical statistical methods
Individual items were evaluated using two key classical
statistical methods: percentage of items at the floor (lowest
response option) of measurement and degree to which in-
dividual items correlated with the overall scale score. Floor
effect refers to a high percentage of patients scoring the
lowest score on an individual item. If floor effects are too
pronounced, it could interfere with the ability of the in-
strument to screen patients as experiencing problems. An
item was considered to have floor effects if greater than
50% of patients endorsed the lowest category. The degree
to which individual items correlated highly with the
remaining items on the scale was measured as the magni-
tude of the correlations ≥ 0.80 [17].
Item response theory methods - rasch analysis
Individual items of the ABSST were evaluated using the
Partial Credit model, an extension of the 1-parameter
Rasch model for use with items using multiple response
formats (dichotomous, polytomous). A Rasch analysis al-
lows for the accumulation of evidence associated with
each response to an item by a group of respondents ra-
ther than relying on group level statistics (i.e., classical
test theory) [20]. More specifically, this particular model
allows for the joint estimation of symptom severity (item
difficulty) and person’s level of severity (person ability).
The underlying assumptions for this item analysis are: 1)
local independence and 2) unidimensionality. Local in-
dependence is evidence that items are conditionally in-
dependent of each other (i.e., each item measures a
unique symptom). Unidimensionality is evidence that
items on a scale measure one underlying trait (e.g., over-
active bladder (OAB) symptoms). In the case of symp-
tom measures, we assume the underlying trait as a
hierarchical symptom structure which may, in fact, be
considered multidimensional. The term unidimensional-
ity, therefore, indicates the underlying symptomology of
the condition.
The ability of the ABSST items to reflect an under-
lying latent construct was assessed by performing item
fit analysis. Infit and outfit statistics compare the actualresponses on the survey with responses predicted along
the range of OAB severity. Acceptable values range from
0.60 – 1.40 for questions with rating scale response op-
tions [18]. Items that do not fit the Rasch model may be
measuring domains other than the domain of interest or
may elicit atypical responses (e.g., endorsement of a high
severity symptom by persons with few symptoms). Two
item fit statistics were calculated: mean-square infit and
mean-square outfit. High infit reflects the tendency of
the item to elicit unexpected responses among respon-
dents whose level on the measure approximates the dif-
ficulty of the item. High outfit reflects the tendency of
the item to elicit unexpected responses among respon-
dents whose level on the measure is above or below the
difficulty of the item. Mean-square infit and outfit statis-
tics ≥ 1.40 indicate significant item misfit.
As a further test of local independence of the ABSST
domains, individual items were evaluated under the
Rasch model using the person separation and reliability,
analogous to the Kuder-Richardson Formula-20 (KR-20)
[20-23]. The KR-20 is defined as a measure of reliability
for dichotomous response choices. Values above 0.90 in-
dicate homogeneity of responses. Under the Rasch
model, KR-20 is used as each response category has a
hypothesized probability of 0.50 of endorsement to the
adjacent category. The item and person separation indi-
ces estimate the separation of persons and items on the
underlying latent variable. Rasch measurement allows
for the additional analysis of both items and persons dis-
tributed along the same linear continuum (trait). In
order to evaluate whether each of the domain items
covers the continuum, items must be sufficiently sepa-
rated in terms of their item difficulty (which can repre-
sent the severity of the underlying trait). The threshold
for separation is an index of 2.0 and an associated separ-
ation reliability of 0.80 [22]. Rasch person reliability
estimates allow for evaluation of whether the items ap-
propriately estimate a person’s symptom severity on the
underlying trait. When reliability falls below the custom-
arily accepted threshold of 0.70, it indicates that patients
may be experiencing symptoms that the measure does
not cover (i.e., construct deficiency) [22]. Rasch item re-
liability estimates the item severity range (i.e., Does the
severity scale associated with the items cover the distri-
bution of severity?); which is considered acceptable if ≥
0.70 as well [22].
Pivot anchoring
In order to create a clinically useful ABSST, a pivot an-
choring analysis was conducted utilizing both novel and
classical test theories to identify optimal items. All 28
recruiting clinicians were asked to review the ABSST
and circle which items were important to them in their
clinical decision making, and at what threshold they
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lem or would be a cause for concern. Twenty-three re-
sponses were received and used in the pivot anchoring
analysis.
A scoring method was developed which included both
the clinician and patient responses. First, the clinicians
referring patients to the quantitative study were sur-
veyed on attributes of the patient population relative to
the instrument. Each clinician was then asked to specify
the lowest rating on each of the 16 items which would
indicate a clinically meaningful potential bladder prob-
lem. Based on the clinicians’ ratings of the items, each
patient’s response was then denoted by either a 1 (indi-
cating a potential bladder problem) or a 0 (indicating no
potential bladder problem). This scoring algorithm was
then tested using classical test theory and item response
theory methods (described in Pivot Anchoring and
Predictive Validity sections).
Predictive validity
Logistic regression was used to determine the predictive
validity of the ABSST total score to identify patients that
would receive a recommendation to see a urologist. The
predictive value was based upon a clinician rating of
‘Yes’ or ‘No’ on whether they would recommend a pa-
tient to see a urologist based upon the patient’s re-
sponses to the ABSST. Results from logistic regression
models testing different cut-points predicting the recom-
mendation were summarized with odds ratio, sensitivity
and specificity, Positive predictive value (PPV), Negative
predictive value (NPV), percent who warranted referral,
and area under the receiver operating curve (ROC). The
odds ratio was defined as those MS patients more likely
to be referred to a urologist than not. The sensitivity re-
fers to those results that are true results (e.g. would refer
to a urologist) while specificity refers to those results
that are truly negative results (e.g. would NOT refer to a
urologist). PPV refers to proportion of positive test re-
sults that are true positives (e.g. proportion of patients
who would be referred to a urologist are warranted to be
referred) while the NPV refers to the proportion of
negative results that are true negatives (e.g. the propor-
tion of patients who would NOT be referred to a urolo-
gist are NOT warranted to be referred). The percent of
those patients who warrant referral is the percentage of
patients classified as either a referral being warranted to
a urologist or not. The area under the ROC refers to the
ability to classify those who would warrant or would not
warrant being referred to a urologist [24].
Results
Patient population
A total of 151 patients, all with MS and with and with-
out NDO, were recruited by 28 clinicians in various USgeographical locations to participate in the study. Pa-
tients had a mean age of 48.2 (SD 12.11) years, with age
ranging from 22 to 80 years of age. Patients had been di-
agnosed with MS an average of 9.1 (SD 7.24) years. Ap-
proximately 70% of patients described the severity of
their MS symptoms over the past 6 months as mild,
23.8% described their symptoms as moderate, 1.3% de-
scribed their symptoms as severe , and 4.6% described
them as none/not applicable (4.6%). Severities were cap-
tured using patient self-report in a demographic form.
Patients were asked how severe their MS symptoms
were in the past 6 months on a 0–3 rating scale (0=Not
applicable / None, 1 = Mild, 2 =Moderate (uses aides to
walk), 3 = Severe (uses wheel chair sometimes)). Ap-
proximately 41% of patients reported having a history of
or currently having urinary incontinence and/or urinary
urgency.
Short form development
Table 1 outlines the results of the predefined statistical
criteria that were developed to ensure that clinically
meaningful and reliable items were included (please
refer to Section 2.2). Eight items (plus the final “Yes/No”
item) were identified from the original 17-item ABSST.
Boxes marked with an (X) represent those items that
met the patient level criteria. The black boxes indicate
those items that met the clinician level analysis or sta-
tistical criteria. The final row in the table indicates im-
portant items from the pivot anchoring analysis. For
example, on Item 1 (Urinate right away), if a clinician
saw that a patient responded with a “4” (All of the time)
then it would be a cause for concern and possibly refer-
ral to a urologist. Item 17 is the “Yes/No” item asking
patients if they would seek help for their bladder issues.
Please see Additional file 1: Table S1 for the ABSST
short form.
Classical statistical results
Evaluation of the classical statistical methods, floor effect
and item correlation statistics, indicated that items 1, 7,
8, 9, 10, and 13 met one or both criteria for inclusion
into the short form. More specifically, items 1, 7, 8, and
9 met the criteria for inclusion into the short form based
on floor effect less than 50%; and items 1, 7, 10 and 13
met the criteria for inclusion into the short form based
on item correlation with scale greater than 80%.
Item response theory Rasch analysis results
Based on the criteria detailed in the methods section,
each of the items on the ABSST demonstrated the
evidenced person reliabilities ≥ 0.70. Fit statistics indi-
cated that 9 item responses were within the expected
criteria (Table 2). However, items 2, 4–6 and 14–16
scored outside of the acceptable ranges, demonstrating
Table 1 Clinician and patient short form results
Criteria Item number
Item 1 Item 3 Item 7 Item 8 Item 9 Item 10 Item 11 Item 13 Item 17
(Urinate
right away)
(Urinary
accidents/
leakage)
(Need to
urinate right
away)
(Wake to
urinate)
(Number of
times urinated)
(Activities with friends
and family affected)
(Ability to
work
affected)
(Embarrassed) (Receive
help)
Floor effect less than 50% X X X X N/A
Item Correlation with Scale greater than
80%
X X X X N/A
Infit statistics between 0.80 and 1.20 X X X X X X N/A
Met all statistical inclusion criteria ++ ++ ++
Greater than 50% of clinicians considered
clinically meaningful
++ ++ ++ ++
Rating Clinician reported as critical for
screening (General MS Patient)
4 3 or 4 4 4 3 or 4 3 or 4 3 or 4 3 or 4 1
X= Patient level analysis.
++= Clinician level analysis.
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Item 16 was shown to not directly measure Impact of
Symptom Intensity as it scored an infit statistic of 2.68
and an outfit of 2.57, both of which are outside of the
threshold of 1.6 – 2.4. This result suggests poor fit to
the Rasch model. Similarly, Items 2, 4, 5, 6, 14, and 15
fell outside of the acceptable range as previously described.
Predictive validity
Results from logistic regression models testing different
cut-points predicting the recommendation to refer to a
urologist are summarized in Table 3. The results of the
odds ratio, sensitivity and specificity, PPV, NPV, and per-
cent correctly classified suggest a raw score of 6 or more
for further evaluation from a urologist. The overall
ABSST Total Score c-statistic was equal to 0.928 and
the logistic regression model was robust (Hosmer and
Lemesow Goodness-of-Fit Test (p=0.5180)).
The performance of the ABSST total score predicting
clinician’s referral to a urologist is presented in Figure 1
via the ROC curve. Figure 1 displays how different cut-
points on the ABSST total score affect sensitivity and
specificity of the prediction for referral to an urologist.
The prediction model across the entire range of clas-
sification thresholds was evaluated; plotting the true
positive identification rate against the false positive rate
(1-Specificity) for various cut scores. In this study, the
cut-point of greater than or equal to a raw score of 6
had a sensitivity of 85.7%, and specificity of 93.1% (i.e.,
85.7% patients would warrant a referral to an urologistTable 2 Infit and outfit statistics by item
Symptom
Bladder Symptoms Intensity
(Separation=9.74; Reliability=0.99)
ITEM 9 (Number of time
ITEM 8 (Wake to urinate
ITEM 7 (Need to urinate
Impact of Bladder Symptoms Intensity
(Separation=3.77; Reliability=0.93)
ITEM 16 (Depressed)
ITEM 10 (Activities with
ITEM 11 (Ability to work
ITEM 13 (Embarrassed)
ITEM 15 (Worried)
ITEM 14 (Frustrated)
Bladder Symptoms Frequency
(Separation=4.40; Reliability=0.95)
ITEM 3(Urinary accidents
ITEM 1(Urinate right awa
Bladder Coping Strategies Frequency
(Separation=4.85; Reliability=0.96)
ITEM 4 (Use of leakage pro
ITEM 5 (Use of leakage pro
ITEM 6 (Limit amount of fl
ITEM 2 (Make sure know w
1Infit and outfit statistics compare the actual responses on the survey with respons
0.60 – 1.40 for questions with rating scale response options [18].and 93.1% of the patients would not warrant a referral
to an urologist).
Discussion
The goal of this study was to validate the short form Ac-
tionable Bladder Symptom Screening Tool (ABSST) as a
patient driven, clinically useful measure that is easy to ad-
minister and score. The goals were to develop a tool that
is sensitive, MS-specific, easy to interpret, easy to use in a
clinical setting, and multidimensional, all of which encour-
age patient-clinician interaction. The unique application of
a mixed methods approach was used to select the best
items from the long form, using both qualitative and
quantitative techniques.
The original, long form ABSST was developed as a de
novo measure after it was determined that existing mea-
sures did not appropriately assess the symptoms and im-
pacts of NDO on MS patients. The long form of the
ABSST is a 17-item instrument (16 items with an add-
itional “Yes/No” item asking patients if they would like
to receive help for their bladder problems) that covers
three domains: Bladder Symptoms, Coping Strategies,
and Impact of Bladder Symptoms. It was developed
using established qualitative methods [25,26], including
a literature review and clinician input to identify poten-
tial symptoms, open-ended concept elicitation interviews
with MS patients who have OAB, and face and content
validity testing through cognitive interviews (face-to-face
debriefing interviews on the ABSST – details to be
reported in another publication) with another group ofInfit MNSQ1 Outfit MNSQ
s urinated) 1.23 0.79
) 0.98 0.97
right away) 0.92 0.89
2.68 2.57
friends and family affected 0.43 1.13
affected) 0.52 1.11
0.64 0.75
0.42 0.75
0.52 0.7
/leakage) 1.14 1.01
y) 0.94 1.01
tection in the day) 1.38 0.96
tection at night) 1.23 1.38
uid) 0.78 0.82
here bathrooms are) 0.67 0.64
es predicted along the range of OAB severity. Acceptable values range from
Table 3 Performance of the revised ABSST total score at various cut-points* predicting Clinician’s Urologist Referral
Cut-Point± Odds
ratio1
Sensitivity2 Specificity3 Positive Negative % Warranting
referral6
c-statistic7
Predictive value (%)4 Predictive value (%)5
>= 21 . 2.04 100.00 100.0 68.0 68.2 0.510
>= 9 55.53 69.39 96.08 89.5 86.7 87.4 0.827
>= 6 81.43 85.71 93.14 85.7 93.1 90.7 0.894
>= 4 33.54 93.88 68.63 59.0 95.9 76.8 0.813
>= 1 8.28 97.96 14.71 35.6 93.8 41.7 0.563
* Only quartiles and key cut points are displayed in the table.
The cut point is defined as different total raw scores on the ABSST ranging from 0 to 24.
1 The odds ratio was defined as those MS patients more likely to be referred to a urologist than not. Values > 1 indicated that the patient is that many more
times (for example 8.28) likely to be referred to a urologist.
2 The sensitivity refers to those results that are true results (e.g. would refer to a urologist). Minimum criteria was ≥0.75.
3 Specificity refers to those results that are truly negative results (e.g. would NOT refer to a urologist). Minimum criteria was ≥0.80.
4 PPV refers to proportion of positive test results that are true positives (e.g. proportion of patients who would warrant a referral to a urologist). Values closer to
100% approximates higher proportion of true positives.
5 NPV refers to the proportion of negative results that are true negatives (e.g. the proportion of patients who would NOT warrant a referral to a urologist are not
referred). Values closer to 100% approximates higher proportions of true negatives.
6 The percent of classified patients is the percentage of patients who are warranted to be referred to a urologist or not.
7 The c-statistic is the area under the ROC curve. Values closer to 1 approximate a perfect model.
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completed, a US-based, non-randomized, multi-center,
stand-alone observational study was carried out to evalu-
ate the measurement properties of the newly developed
instrument. Analysis of item completion, item and scale
distribution, and predictive validity of the long form
ABSST demonstrated strong psychometric properties (de-
tails reported in another publication) [17,19,27-30]. The
ABSST total score also demonstrated predictive validity,
identifying patients who would receive a referral. In order
to demonstrate that this screening tool was valid and reli-
able as a short form, classical test theory and itemFigure 1 ROC Curve of the ABSST Total Score at Cut-Points
Predicting Referral to a Urologist.response theory approaches were taken to ensure that
each item included provided the most information, was
clinically meaningful, and demonstrated predictive attri-
butes for patient referral to a urologist. Overall, concur-
rent validity for each subscale as well as predictive and
concurrent validity of the total instrument were shown,
demonstrating strong psychometric properties.
The simplified scoring method for bladder problem as-
sessment developed here will make it easier for clinicians
to identify patients with MS who may have potential
problems. The approach used to develop the scoring al-
gorithm adheres to the FDA guidance, is psychometric-
ally valid, and appropriately utilizes pivot anchoring [31],
which has been widely used in the interpretation of clin-
ically meaningful points along a categorical continuum.
This methodology allowed for synthesis of meaningful
cut-points along the continuum where patients are likely
to demonstrate urinary problems, as reported by clini-
cians. This mixed statistical methods approach to item
reduction and scoring optimizes selection of items for
making sound clinical decisions based on clinicians’ as-
sessment of the need for patient referral. These data,
when subjected to predictive validity calculations, pro-
vided very strong results indicating that clinicians could
use it to refer patients appropriately.
This study has several limitations. First, the ABSST is
a screening tool and was not designed for diagnostic
purposes. Second, although it was identified as being
clinically meaningful, the relevance in overall clinical
practice has not yet been tested. Lastly, because of the
error range on the tool itself, it is possible that some pa-
tients’ symptoms may go untreated (under-sensitive re-
sults) while other patients may incur unnecessary tests
and costs (under-specified results). However, the specifi-
city and sensitivity are strong which indicates that the
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would likely benefit from a referral from those who
would not.
Other questionnaires have been developed such as an
8-item screening tool to aid in identifying patients who
may have OAB in a busy primary care setting which has
a sensitivity of 98% and specificity of approximately 83%
[32]. Moreover, the 3-Item OAB awareness tool (which
is a short version of the 8-item screening tool) has re-
cently been validated with a sensitivity of 82% and speci-
ficity of 91%. In addition, the International Prostate
Symptom Score IPSS has been used to identify the se-
verity of bladder symptoms in an MS population (All pa-
tients had an Expanded Disability Status Scale score
of <6.5, with a mean of 3.4). The 8-item IPSS was origin-
ally developed to measure symptom severity in benign
prostate hyperplasia. It has also been utilized to measure
the prevalence of bladder problems over 2–3 years [33].
Only the ABSST Short Form has been developed or psy-
chometrically tested to the scientific rigor of the FDA
Guidance for PRO development. Overall the short form
ABSST demonstrated good sensitivity and specificity as
it has a positive predictive value of approximately 86%
and a negative predictive value of approximately 93%.
This shows that the short form ABSST maintains the in-
tegrity of the longer form tool which had a positive pre-
dictive value of approximately 76% and a negative
predictive value of approximately 95% [16]. The sensitiv-
ity and specificity of the short form ABSST are in-line
with other validated tools in the field and demonstrate
its strength and potential positive impact in a clinic and
primary care setting [34]. Of particular importance is the
ability of the tool to detect more true-positive cases
which increase the cost-effectiveness of screening and
early detection of OAB problems as opposed to the
false-positive cases, which can be detrimental to the
screening process.
Conclusions
The simplified scoring method of the ABSST allows for
clinicians to easily identify patients with MS who may
have potential urinary problems. The approach used to
develop the scoring algorithm adheres to the FDA guid-
ance, is psychometrically valid, and appropriately utilizes
pivot anchoring [31], which has been widely used in the
interpretation of clinically meaningful points along a cat-
egorical continuum. The methodology allowed for syn-
thesis of meaningful cut-points where patients are likely
to demonstrate urinary problems, as reported by clini-
cians. The reduction in items and scoring optimizes the
most informational items for making sound clinical deci-
sions. These data, when subjected to predictive validity
calculations, indicate that clinicians can use the ABSST
to refer patients appropriately. In conclusion, ABSSTprovides a new method for assessing bladder problems
among MS patients, and may facilitate earlier diagnosis,
treatment, and referral to a specialist.
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